1. Home
  2. BLLN vs CZR Comparison

BLLN vs CZR Comparison

Compare BLLN & CZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BillionToOne Inc.

BLLN

BillionToOne Inc.

HOLD

Current Price

$98.28

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Logo Caesars Entertainment Inc.

CZR

Caesars Entertainment Inc.

HOLD

Current Price

$30.14

Market Cap

6.1B

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLLN
CZR
Founded
2016
1937
Country
United States
United States
Employees
713
15500
Industry
Medical Specialities
Hotels/Resorts
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
6.1B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
BLLN
CZR
Price
$98.28
$30.14
Analyst Decision
Buy
Buy
Analyst Count
7
13
Target Price
$126.71
$31.92
AVG Volume (30 Days)
784.7K
3.3M
Earning Date
05-06-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,473,504,000.00
Revenue This Year
$46.29
$3.56
Revenue Next Year
$30.14
$2.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
65.03
52 Week Low
$61.96
$17.86
52 Week High
$150.44
$30.88

Technical Indicators

Market Signals
Indicator
BLLN
CZR
Relative Strength Index (RSI) 37.20 57.13
Support Level $73.46 $29.50
Resistance Level $108.50 $30.86
Average True Range (ATR) 8.11 0.23
MACD -5.35 0.00
Stochastic Oscillator 15.41 87.84

Price Performance

Historical Comparison
BLLN
CZR

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

About CZR Caesars Entertainment Inc.

Caesars Entertainment's stand-alone portfolio includes about 50 domestic gaming properties across the Las Vegas (48% of 2025 EBITDAR) and regional (49%) markets. Additionally, the company hosts managed properties and digital assets that produced marginal EBITDA in 2025. Caesars' US presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the US portion of William Hill (it sold the international operation in 2022), a digital sports betting platform. The portfolio is set to expand to more than 60 casinos with the proposed acquisition of Caesars by Fertitta Entertainment and its Golden Nugget resorts.

Share on Social Networks: